ateganosine
Phase 1Small molecule
ateganosine is one of 7 small molecule programs targeting Resectable Hepatocellular Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Resectable Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 2
Imfinzi
AstraZenecaPhase 1
Imjudo
AstraZenecaPhase 1
Cadonilimab
SShanghai Pharmaceuticals Holding Co., Ltd
Phase 1
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Preclinical
ateganosine
UUniversity of Texas Southwestern Medical Center
Phase 1
IBI310
Innovent Biologics (Suzhou) Co. Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ateganosine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details